Akebia Therapeutics (AKBA) executive compensation, 2026 proxy

John P. Butler, President and Chief Executive Officer, was paid $5.7M in 2025, up 33% from $4.3M the year before. The CEO-to-median-employee pay ratio was 21:1, on median employee pay of $270,410.

Filed
April 28, 2026
Annual meeting
June 17, 2026
Pay year
2025
Named executives
4
CEO total pay
$5.7M+33% vs prior year
CEO to median employee
21:1median $270,410
CEO pay in equity
74%$4.2M in awards
CEO Base Salary
$864,010Fiscal 2025
2025 Corporate Achievement
90%For annual cash bonuses
CEO Target Bonus Percentage
75%Of base salary

How Butler was paid

$5.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Stock awards38%Option awards36%Non-equity incentive10%All other compensation0%

Named executive officers

ExecutiveTotal
John P. ButlerPresident and Chief Executive Officer$5,652,339
Erik J. OstrowskiSenior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer$1,792,361
Steven K. Burke, M.D.Senior Vice President, Chief Research & Development and Medical Officer$1,859,815
Nicholas P. GrundSenior Vice President, Chief Commercial Officer$1,728,405

What changed and why

  • $5.7MCEO John P. Butler received total compensation of $5,652,339 in fiscal 2025.
  • 90%Annual cash bonuses were paid based on 90% achievement of corporate performance goals.
  • Named executive officers received annual merit-based salary increases and equity incentive awards.
  • Amended executive severance agreements eliminated single-trigger equity vesting upon a change in control.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.